CN115634240A - Luteolin green algae hydrogel preparation and preparation method and application thereof - Google Patents
Luteolin green algae hydrogel preparation and preparation method and application thereof Download PDFInfo
- Publication number
- CN115634240A CN115634240A CN202211196036.2A CN202211196036A CN115634240A CN 115634240 A CN115634240 A CN 115634240A CN 202211196036 A CN202211196036 A CN 202211196036A CN 115634240 A CN115634240 A CN 115634240A
- Authority
- CN
- China
- Prior art keywords
- luteolin
- preparation
- solution
- green algae
- quaternized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a luteolin hydrogel preparation and a preparation method and application thereof, and provides application of luteolin and/or green algae in preparation of a medicine for treating wounds difficult to heal due to diabetes. Furthermore, the invention provides a luteolin green algae hydrogel preparation which is uniform and fine in shape, stable in property, safe and effective, can be applied to dermatology, such as treatment of wounds difficult to heal by diabetes, and is high in bioavailability. In the luteolin-green algae hydrogel preparation provided by the invention, luteolin-green algae are used in a combined manner, and unexpected technical effects of 1+1 > 2 can be achieved in the treatment of wounds which are difficult to heal by diabetes; the invention also provides a preparation method of the luteolin-green algae hydrogel preparation, the process is simple, and the obtained luteolin-green algae hydrogel preparation has good storage stability.
Description
Technical Field
The invention relates to the technical field of pharmaceutical preparations, in particular to a luteolin hydrogel preparation and a preparation method and application thereof.
Background
Luteolin exists in various plants in the form of glucoside, and the plants have high content of dracocephalum heterophyllum benth, capsicum, wild chrysanthemum, honeysuckle and perilla frutescens. Luteolin (luteolin) is a natural flavonoid found in a variety of plants. Has various pharmacological activities such as anti-inflammation, anti-allergy, uric acid reduction, anti-tumor, antibacterial and antivirus, and is mainly used for relieving cough, eliminating phlegm, diminishing inflammation, reducing uric acid, treating cardiovascular diseases, treating amyotrophic lateral sclerosis, SARS, hepatitis and the like in clinic.
Diabetes can affect every organ of the body, including the skin. It is estimated that more than 65% of diabetics develop skin problems. And compared with healthy people, the diabetic patients are more prone to premature skin aging, skin itch, skin infection, such as infection secondary to foot ulcer and other skin problems. The chronic difficult-to-heal skin wound of the diabetes is caused by ischemia and tissue nutrition disorder due to nerve and vascular diseases and the like, and the chronic difficult-to-heal skin wound is easy to have the symptom of long-term unhealed wound in the wound repair process. In the later period of injury, the wounds which are difficult to heal are easy to be secondarily infected by bacteria due to the continuous injury of the epithelium, the damage of the defense mechanism of the organism and the like.
Therefore, it is necessary to provide a drug for effectively treating wounds which are difficult to heal in diabetes.
Disclosure of Invention
The present invention aims to solve at least to some extent one of the technical problems of the prior art, and therefore, in a first aspect of the invention, the invention provides the use of luteolin and/or green algae in the preparation of a medicament for treating diabetic wounds which are difficult to heal.
The structural formula of the luteolin is shown as follows:
in a second aspect of the invention, the invention provides a pharmaceutical formulation comprising luteolin and/or a green alga.
In one or more embodiments of the invention, the pharmaceutical formulation is a hydrogel formulation.
In one or more embodiments of the invention, the pharmaceutical formulation includes luteolin and green algae;
specifically, the concentration ratio of the luteolin to the green algae is 0.5-10.
In one or more embodiments of the invention, the luteolin green algae hydrogel has a strength in the range of 100 to 10000Pa, preferably 1700Pa.
In a third aspect of the invention, there is provided a process for the preparation of a pharmaceutical formulation according to the second aspect of the invention, comprising the steps of:
step 1): preparing quaternized chitin or quaternized chitosan: carrying out homogeneous reaction on chitin or chitosan and a quaternization reagent in an alkali/urea system to obtain quaternized chitin or quaternized chitosan;
step 2): preparing a quaternized chitin or quaternized chitosan solution: dissolving the quaternized chitin or quaternized chitosan prepared in the step 1) in Phosphate Buffer Solution (PBS) to obtain quaternized chitin or quaternized chitosan solution;
and step 3): preparation of the crosslinking agent: carrying out oxidation reaction on natural polysaccharide to obtain a cross-linking agent;
and step 4): dissolving the cross-linking agent obtained in the step 3) in water to obtain a cross-linking agent solution;
and step 5): preparation of luteolin solution: dissolving luteolin in the quaternized chitin or quaternized chitosan solution obtained in the step 2) to obtain the luteolin solution;
step 6): preparation of luteolin green algae hydrogel: mixing the cross-linking agent solution obtained in the step 4) with the luteolin solution obtained in the step 5), and adding the green algae solution to obtain the luteolin-green algae hydrogel.
In one or more embodiments of the present invention, in the step 2), the concentration of the quaternized chitin or quaternized chitosan solution is controlled to be 0.5-10% (w/v).
In one or more embodiments of the present invention, in the step 3), the natural polysaccharide is selected from one or more of dextran, alginic acid and hyaluronic acid; preferably, the oxidation reaction comprises: dissolving natural polysaccharide in water, adding NaIO 4 The reaction was stirred in the aqueous solution under dark.
In one or more embodiments of the present invention, in the step 4), the concentration of the crosslinking agent solution is controlled to be 0.5 to 10% (w/v).
In one or more embodiments of the invention, in the step 5), the concentration of luteolin in the luteolin solution is 5mg/mL.
In one or more embodiments of the invention, in the step 6), the concentration of the green algae in the green algae solution is 50 μ g/ml.
Preferably, the crosslinker solution obtained in step 4) is mixed with the luteolin solution obtained in step 5) in equal volumes.
In a fourth aspect, the invention provides a pharmaceutical preparation according to the second aspect and/or a method for preparing a pharmaceutical preparation according to the third aspect, for use in preparing a medicament for treating a diabetic hard-to-heal wound.
The preparation method of the green alga solution comprises the following steps: culturing green algae in Zarrouk culture medium at 30 deg.C under illumination for 12 hr and in darkness for 12 hr to obtain green algae solution.
The clinical application of luteolin is mainly oral administration, including tablets, capsules, injections and the like. However, the bioavailability is low because the drug is degraded in the gastrointestinal tract when orally administered. Therefore, the traditional administration mode of the luteolin is not an ideal administration mode of the dermatological drug, so that the research on a new dosage form changes the administration route of the luteolin, and the treatment effect of locally treating the wounds which are difficult to heal by diabetes is improved.
The invention has the beneficial effects that:
1. the invention provides application of luteolin and/or green algae in preparation of a medicine for treating diabetes mellitus wound difficult to heal;
2. the luteolin green algae hydrogel preparation provided by the invention is uniform and fine in shape, stable in property, safe and effective, can be applied to dermatology, is used for treating wounds which are difficult to heal by diabetes, and has no irritation and allergy, good absorbability, high safety and high bioavailability;
3. in the luteolin-green algae hydrogel preparation provided by the invention, luteolin-green algae are used in a combined manner, and unexpected technical effects of 1+1 > 2 can be achieved in the treatment of wounds which are difficult to heal by diabetes;
4. the invention provides a preparation method of a luteolin-green algae hydrogel preparation, which has simple process, and the obtained luteolin-green algae hydrogel preparation has good storage stability; use of the hydrogel preparation of the present invention
Drawings
FIG. 1 is a graph comparing the results of near infrared two-zone imaging in control group, CCOD group, DM-TGO group, CCOD @ Alg group, and Alg group at different times (day 2, day 6, day 12, day 16) after administration;
FIG. 2 is a graph showing the results of the mean fluorescence intensity in the near infrared two-zone imaging region on the 16 th day after administration in the control group, CCOD group, DM-TGO group, CCOD @ Alg group, and Alg group;
FIG. 3 is a graph showing the comparison of the morphological observation results of the diabetic non-healing wounds in the control group, CCOD group, DM-TGO group, CCOD @ Alg group and Alg group.
Detailed Description
The scheme of the invention will be explained with reference to the examples. It will be appreciated by those skilled in the art that the following examples are illustrative of the invention only and should not be taken as limiting the scope of the invention. The examples, where specific techniques or conditions are not indicated, are to be construed according to the techniques or conditions described in the literature in the art or according to the product specifications. The following examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer, by using conventional methods known in the art without specific descriptions, and by using consumables and reagents which were commercially available without specific descriptions. Unless otherwise defined, technical and scientific terms used herein have the same meaning as is familiar to those skilled in the art. In addition, any methods or materials similar or equivalent to those described herein can also be used in the present invention.
Example 1
The preparation method of the quaternized chitin or the quaternized chitosan comprises the following steps:
preparing 98g of aqueous solution containing 2wt% of KOH and 4wt% of urea, precooling to-30 ℃, adding 2g of chitin or chitosan at room temperature, and mechanically stirring for 30 minutes to obtain transparent and clear 2wt% chitin or chitosan solution; adding 3-chloro-2-hydroxypropyl trimethyl ammonium chloride into the obtained chitin or chitosan solution to ensure that the molar ratio of the quaternizing agent (3-chloro-2-hydroxypropyl trimethyl ammonium chloride) to the chitin unit is 4:1, stirring for 24 hours, and then adding HCl to neutralize the reaction solution; dialyzing the reaction solution by distilled water for 7 days, and freeze-drying to obtain the white fibrous quaternized chitin or quaternized chitosan.
The quaternized chitin or quaternized chitosan is prepared according to the method, experimental groups 1-12 are implemented, the preparation condition difference points of the experimental groups 1-12 and the properties of the obtained quaternized chitin or quaternized chitosan are shown in the following table 1.
Table 1 Experimental groups 1-12 for preparing the difference point of the conditions of the quaternized chitin or the quaternized chitosan and the properties of the obtained quaternized chitin or the quaternized chitosan
Example 2
The preparation method of the cross-linking agent comprises the following steps: the cross-linking agent is prepared by oxidation reaction of natural polysaccharide (dextran, sodium alginate and hyaluronic acid), and comprises the following specific steps: dissolving natural polysaccharide (dextran, sodium alginate and hyaluronic acid) in 150mL of water to obtain a polysaccharide solution with a certain concentration of 1-5 (w/v)%, and dropwise adding NaIO dissolved in 10mL of water in advance 4 Stirring in the dark for 2h, adding 0.4mL of ethylene glycol to terminate the reaction, and stirring for 1hDialyzing, and freeze-drying to obtain oxidized polysaccharide (cross-linking agent).
Oxidized polysaccharides were prepared according to the above method, with the differences shown in table 2 below.
TABLE 2 differentiation points of the conditions for preparing oxidized polysaccharides and the Properties of the oxidized polysaccharides obtained in Experimental groups 1 to 12
Example 3
The preparation method of the green alga solution comprises the following steps: culturing green algae in Zarrouk culture medium at 30 deg.C for 12 hr under illumination and in dark for 12 hr alternately to obtain green algae solution with green algae concentration of 50 μ g/mL, wherein the Zarrouk culture medium has the following components: 16.8g/L NaHCO 3 ,2.5g/L NaNO 3 ,1g/L NaCl,0.5g/L K 2 HPO 4 ,1g/L K 2 SO 4 ,0.2g/L MgSO 4 ·7H 2 O,0.08g/L EDTA,0.01g/L FeSO 4 ·7H 2 O,0.08g/L CaCl 2 ·2H 2 O,5.72mg/L H 3 BO 3 ,0.04mg/L(NH 4 ) 6 Mo 7 O 24 ,3.6mg/L MnCl 2 ·4H 2 O,0.16mg/L CuSO 4 ·5H 2 O and 0.44mg/L ZnSO 4 ·7H 2 O. wherein the green algae were purchased from wuhan light biotechnology limited.
The preparation of luteolin chlorella hydrogel preparation comprises the following steps: the chitin quaternary ammonium salt or the chitosan quaternary ammonium salt obtained in the embodiment 1 is dissolved in Phosphate Buffer Solution (PBS) to prepare chitin quaternary ammonium salt or chitosan quaternary ammonium salt solution with the concentration of 0.5-10% (w/v), and then the oxidized polysaccharide obtained in the embodiment 2 is dissolved in water to prepare solution with the concentration of 0.5-10% (w/v). Dissolving luteolin in chitin quaternary ammonium salt or chitosan quaternary ammonium salt solution (1 mL), controlling the concentration of luteolin to be 5mg/mL, mixing the obtained quaternized chitin or quaternized chitosan solution containing luteolin with oxidized polysaccharide solution in equal volume, and adding green algae solution with concentration of 50 μ g/mL. The concentration ratio of the green algae to the luteolin is 0.5-10 and the luteolin-green algae hydrogel preparation is obtained by mixing the green algae and the luteolin.
The luteolin-green algae hydrogel preparation prepared according to the above method has the differences in preparation conditions and the strengths of the luteolin-green algae hydrogel preparation as shown in table 3 below.
Table 3 differences between the conditions for preparing the luteolin-green algae hydrogel preparations and the properties of the obtained luteolin-green algae hydrogel preparations in the experimental groups 1 to 12
Example 4
Preparation of luteolin hydrogel formulation, as follows: the chitin quaternary ammonium salt or the chitosan quaternary ammonium salt obtained in the embodiment 1 is dissolved in Phosphate Buffer Solution (PBS) to prepare chitin quaternary ammonium salt or chitosan quaternary ammonium salt solution with the concentration of 2% (w/v) respectively, and then the oxidized polysaccharide obtained in the embodiment 2 is dissolved in water to prepare solution with the concentration of 1% (w/v). Dissolving luteolin in chitin quaternary ammonium salt or chitosan quaternary ammonium salt solution (1 mL), controlling the concentration of luteolin to be 5mg/mL, mixing the obtained quaternized chitin or quaternized chitosan solution containing luteolin with oxidized polysaccharide solution in equal volume, and adding 10mL Zarrouk culture medium to obtain the luteolin green algae hydrogel preparation.
Example 5
The green algae solution was prepared as in example 3.
Preparation of a green algae hydrogel formulation, as follows: the chitin quaternary ammonium salt or the chitosan quaternary ammonium salt obtained in the embodiment 1 is dissolved in Phosphate Buffer Solution (PBS) to prepare chitin quaternary ammonium salt or chitosan quaternary ammonium salt solution with the concentration of 2% (w/v) respectively, and then the oxidized polysaccharide obtained in the embodiment 2 is dissolved in water to prepare solution with the concentration of 1% (w/v). Mixing the obtained quaternized chitin or quaternized chitosan solution (1 mL) with oxidized polysaccharide solution in equal volume, and adding green algae solution with concentration of 50 μ g/mL. Mixing to obtain the green algae hydrogel preparation.
Example 6
Evaluation of Properties
Pharmacodynamic evaluation of wound healing difficulty in treating diabetes of mice
The luteolin green algae hydrogel preparation has good curative effect and small side effect when being used for treating the mouse diabetes mellitus wound which is difficult to heal, a mouse diabetes mellitus model is established by using Streptomycin (STZ) intraperitoneal injection in the experiment, and the treatment condition of the hydrogel is treated and evaluated by using the luteolin green algae hydrogel preparation, so that the novel and effective external preparation for treating the diabetes mellitus wound which is difficult to heal is prepared.
Test materials and methods
Experimental reagent: streptomycin (Sigma company); green algae (photo biotechnology limited); luteolin (Shanghai Bigdi medicine science and technology Co., ltd.); glucometer (Beijing Yicheng BioElectron technology, inc.); pH meter (Shanghai Mey Teller Co.).
Instrument for measuring the position of a moving object
Electronic scales (emri trade, inc. Yongkang); pet razor (Ningbo Aikelipi electric appliance Co., ltd.)
Experimental animals: mouse (BALB/c, male, 18-22 g, university of three gorges animal experiment center)
Construction of type 1 diabetic mouse model: model induction was performed using multiple small dose STZ dosing. The 50 male BALB/c mice were bred by conventional adaptation for 2 weeks, and then the mice were molded and randomly divided into a control group (10), a CCOD group (10), a DM-TGO group (10), a CCOD @ Alg group (10) and an Alg group (10). The model mice were injected with STZ solution (50 mg/kg) intraperitoneally for 5 consecutive days, and fasted for 8h before injection without water deprivation. The injection is prepared by dissolving STZ in 0.1mol/L citric acid buffer solution (pH 4.5), and dissolving in ice away from light for 30 min.
Constructing a type 1 diabetic mouse difficult-to-heal wound model: skin wounds were made according to the earlier study method. Anaesthetizing the mouse (the dosage of the anaesthetic is 45 mg/kg), then using an animal shaver to disinfect Mao Tichu at the highest point of the back of the mouse with iodophor, and using sterile scissors and tweezers to make a round wound with the diameter of 1cm on the back, wherein the whole skin is as deep as the fascia layer.
Experimental grouping and dosing: the test results were divided into control group (10), CCOD group (10), DM-TGO group (10), CCOD @ Alg group (10), and Alg group (10). Control group did not treat; the CCOD group was treated with the luteolin hydrogel prepared in example 4; the DM-TGO group adopts a local oxygen blowing treatment method, and oxygen is blown for 15 minutes every time and once a day; the ccod @ Alg group was treated with the luteolin green alga hydrogel prepared in experiment group 6 of example 3, and the Alg group was treated with the green alga hydrogel prepared in example 5.
The CCOD group, CCOD @ Alg group and Alg group were administered once a day, 1mL each time.
Evaluation method
1. Morphological observation of wound healing
H and E staining
TNF-alpha, interleukin-6
4. Near-infrared two-zone fluorescence imaging
Results of the experiment
FIG. 1 is a comparison graph of near infrared two-zone imaging results of a control group, a CCOD group (CC + OD group), a DM-TGP group, a CCOD @ Alg group and an Alg group at different times (day 2, day 6, day 12 and day 16) after administration, and as can be seen from the graph, signals of the CCOD @ Alg group are obviously lower than those of other treatment groups, which proves that the luteolin chlorella hydrogel has a remarkable treatment effect on wounds which are difficult to heal by diabetes;
FIG. 2 is a graph showing the results of the mean fluorescence intensity in the near infrared two-zone imaging region on the 16 th day after administration in the control group, CCOD group (CC + OD group), DM-TGP group, CCOD @ Alg group and Alg group; as can be seen from the figure, the fluorescence intensity of the CCOD group is reduced 1199, the fluorescence intensity of the Alg group is reduced 1240, and the fluorescence intensity of the CCOD @ Alg group is reduced 3070, which indicates that luteolin and green algae produce obvious synergistic effect on the treatment of the wounds which are difficult to heal by diabetes.
FIG. 3 is a graph showing the comparison result of the morphological observation of the diabetic non-healing wounds of the control group, the CCOD group, the DM-TGP group, the CCOD @ Alg group and the Sal group, and it can be seen from the graph that the healing condition of the CCOD @ Alg group is better than that of the other treatment groups, and the therapeutic effect of the luteolin chlorella hydrogel on the diabetic non-healing wounds is confirmed.
Although the embodiments of the present invention have been shown and described, it is understood that the above embodiments are illustrative and not restrictive, and that those skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention and that they should be included in the protection scope of the present invention.
Claims (10)
1. Application of luteolin and/or green algae in preparing medicine for treating diabetic wound difficult to heal is provided.
2. A pharmaceutical formulation comprising luteolin and/or a green alga.
3. The pharmaceutical formulation of claim 2, wherein the pharmaceutical formulation is a hydrogel formulation.
4. The pharmaceutical formulation according to claim 2 or 3, wherein the pharmaceutical formulation comprises luteolin and green algae;
preferably, the concentration ratio of luteolin to green algae is 0.5-10.
5. A pharmaceutical formulation according to claim 2 or 3, wherein the luteolin green alga hydrogel has a strength in the range of 100 to 10000Pa, preferably 1700Pa.
6. A process for the preparation of a pharmaceutical formulation according to any one of claims 2 to 5, comprising the steps of:
step 1): preparing quaternized chitin or quaternized chitosan: carrying out homogeneous reaction on chitin or chitosan and a quaternization reagent in an alkali/urea system to obtain quaternized chitin or quaternized chitosan;
step 2): preparing a quaternized chitin or quaternized chitosan solution: dissolving the quaternized chitin or quaternized chitosan prepared in the step 1) in Phosphate Buffer Solution (PBS) to obtain quaternized chitin or quaternized chitosan solution;
step 3): preparation of the crosslinking agent: carrying out oxidation reaction on natural polysaccharide to obtain a cross-linking agent;
step 4): dissolving the cross-linking agent obtained in the step 3) in water to obtain a cross-linking agent solution;
step 5): preparation of luteolin solution: dissolving luteolin in the quaternized chitin or quaternized chitosan solution obtained in the step 2) to obtain the luteolin solution;
step 6): preparation of luteolin green algae hydrogel: mixing the cross-linking agent solution obtained in the step 4) with the luteolin solution obtained in the step 5), and adding the green algae solution to obtain the luteolin-green algae hydrogel.
7. The method for preparing a pharmaceutical preparation according to claim 6, wherein in the step 2), the concentration of the quaternized chitin or quaternized chitosan solution is controlled to be 0.5-10% (w/v); preferably, in the step 3), the natural polysaccharide is selected from one or more of dextran, alginic acid and hyaluronic acid; preferably, the oxidation reaction comprises: dissolving natural polysaccharide in water, adding NaIO 4 The reaction mixture was stirred in the dark.
8. The method for preparing a pharmaceutical formulation according to claim 6, wherein in the step 4), the concentration of the cross-linking agent solution is controlled to be 0.5 to 10% (w/v); preferably, in the step 6), the concentration of luteolin in the luteolin solution is 5mg/ml.
9. The method of claim 6, wherein in step 6), the concentration of green algae in the green algae solution is 50 μ g/ml; preferably, the crosslinker solution obtained in step 4) is mixed with the luteolin solution obtained in step 5) in equal volumes.
10. Use of a pharmaceutical preparation according to claims 2-5 and/or a process for the preparation of a pharmaceutical preparation according to claims 6-9 in the preparation of a medicament for the treatment of diabetic refractory wounds.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211196036.2A CN115634240A (en) | 2022-09-29 | 2022-09-29 | Luteolin green algae hydrogel preparation and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211196036.2A CN115634240A (en) | 2022-09-29 | 2022-09-29 | Luteolin green algae hydrogel preparation and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115634240A true CN115634240A (en) | 2023-01-24 |
Family
ID=84942826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211196036.2A Pending CN115634240A (en) | 2022-09-29 | 2022-09-29 | Luteolin green algae hydrogel preparation and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115634240A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2578422A1 (en) * | 1985-03-05 | 1986-09-12 | Cariel Leon | Therapeutic composition for external topical use, based on luteolin, and process for preparing it |
| JP2007516225A (en) * | 2003-05-14 | 2007-06-21 | エンドゥマトリクス，インコーポレイテッド | Seaweed composition for the treatment of diabetes and diabetic complications |
| KR20130140448A (en) * | 2012-06-14 | 2013-12-24 | 부경대학교 산학협력단 | Pharmaceutical compositions for prevention or treatment of diabetic complications comprising an extract of capsosiphon fulvescens or the compounds isolated from thereof |
| CN113876788A (en) * | 2021-10-29 | 2022-01-04 | 武汉大学 | Salidroside hydrogel preparation and preparation method and application thereof |
-
2022
- 2022-09-29 CN CN202211196036.2A patent/CN115634240A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2578422A1 (en) * | 1985-03-05 | 1986-09-12 | Cariel Leon | Therapeutic composition for external topical use, based on luteolin, and process for preparing it |
| JP2007516225A (en) * | 2003-05-14 | 2007-06-21 | エンドゥマトリクス，インコーポレイテッド | Seaweed composition for the treatment of diabetes and diabetic complications |
| KR20130140448A (en) * | 2012-06-14 | 2013-12-24 | 부경대학교 산학협력단 | Pharmaceutical compositions for prevention or treatment of diabetic complications comprising an extract of capsosiphon fulvescens or the compounds isolated from thereof |
| CN113876788A (en) * | 2021-10-29 | 2022-01-04 | 武汉大学 | Salidroside hydrogel preparation and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| "《绿藻（蛋白核小球藻）促进伤口复原人体实验》", Retrieved from the Internet <URL:https://zhuanlan.zhihu.com/p/164941109> * |
| "Wound healing effect of flavonoid rich fraction and luteolin isolated from Martynia annua Linn. on streptozotocin induced diabetic rats", 《亚太热带医药杂志（英文版）》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR860001148B1 (en) | Method for preparing hyaluronic acid having pharmaceutical activity | |
| KR101155884B1 (en) | Chemically modified polyaminosaccharide by a hydrocarbyl sultone compound | |
| JPH07505378A (en) | Wound treatment treatment for fibrotic disorders | |
| KR101825041B1 (en) | Skin External composition for treating a wound comprising substance P | |
| CN102949709A (en) | External gel used for treating diabetic foot, and preparation method and application thereof | |
| CN102558391B (en) | vitamin E succinate-chitosan graft and preparation method and application thereof | |
| CN108366975A (en) | Treatment using deoxycholic acid and its salt to the fat of accumulation | |
| JPWO2008053728A1 (en) | Biohealing promoter | |
| CN108837140B (en) | Preparation method and application of earthworm protein microsphere nano wound compound | |
| CN110431154B (en) | Hyaluronic acid cross-linked with natural or semi-synthetic cross-linking agents | |
| CN115634240A (en) | Luteolin green algae hydrogel preparation and preparation method and application thereof | |
| CN102363040B (en) | Antimicrobial peptide preparation for mucosal tissues | |
| CN103860444B (en) | Contain the siRNA cell culture cleawhite over-night essences for suppressing melanin generation | |
| CN102652830B (en) | Application of Cathelicidin-BF (bungarus fasciatus) in preparation of antineoplastic medicament | |
| RU2473349C1 (en) | Pharmaceutical composition for treating burns | |
| CN107596355A (en) | A kind of Medical pain easing, the exterior-applied gel subsided a swelling, brought down a fever and preparation method thereof | |
| DE60203895T2 (en) | USE OF N-ACETYL-D-GLUCOSAMINE IN THE MANUFACTURE OF A MEDICAMENT FOR SUPPRESSING THE SIDE EFFECTS OF RADIOTHERAPY AND CHEMOTHERAPY | |
| CN104961831A (en) | Modified recombinant human endostatin and application thereof | |
| CA2986941C (en) | New use of isoquinoline derivatives for diabetic wound healing | |
| CN111265594A (en) | Medicinal preparation for repairing wound and preparation method thereof | |
| Chen et al. | Novel Application of Immunomodulatory Mushroom Polysaccharide (β-Glucan) and Triterpenes for Diabetic Wound Care | |
| US20220402763A1 (en) | Graphene oxide (go)-based composite nanoparticle drug delivery system and preparation method thereof | |
| RU2437675C1 (en) | Haemostimulating medication | |
| CN116236504A (en) | Application of ferric sulfide nano enzyme in preparing medicament for treating acute kidney injury related diseases | |
| TWI610678B (en) | Use of citrus polyphenol for wound healing and composition thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |